"Q. Two product-specific questions, please. Firstly, for Zolgensma\u00ae in the US, I think you said at your last set of results that you had 74% newborn coverage, and your goal now is, I think, 80% by the end of the year, if I heard it right. Does that mean that you think that access is only really going to expand sort of incrementally in the US this year? And sort of in practical terms, there won't be very much extra? Or is there a more optimistic scenario in there?"